We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KAI:NYSEKadant Inc Analysis

Data as of 2026-04-12 - not real-time

$325.03

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Kadant Inc. posted a record Q4 revenue of $286.2 million, up 11% YoY, and generated strong operating cash flow, supporting an increase in the quarterly dividend to $0.36 per share (a 15% payout). Technical indicators show the stock trading above its 20‑day (302) and 50‑day (321) SMAs with a neutral trend, while the MACD histogram is positive (bullish signal) and the RSI sits at 58, suggesting modest upside momentum but no overbought condition. The price of $325 is near the identified resistance level of $328.6, with support around $280, indicating limited short‑term upside. Valuation metrics reveal a trailing PE of 37.6 versus an industry average of 30.9 and a DCF fair value of $154.9, implying the market is pricing significant growth expectations into the stock. High beta (1.65) and 30‑day volatility of 45% highlight elevated market risk, yet the low payout ratio and solid free cash flow underpin dividend sustainability. Overall, the company combines robust earnings growth and cash generation with a premium valuation and heightened price volatility, suggesting a cautious but opportunistic stance for investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with limited upside
  • Bullish MACD histogram but neutral trend
  • Stable volume and modest RSI

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 11% YoY revenue growth and strong cash generation
  • Dividend increase with low payout ratio
  • Growth‑oriented valuation despite premium price

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustained earnings growth and sector positioning
  • High beta and volatility tempering long‑term price appreciation
  • Overvalued relative to DCF but solid fundamentals

Key Metrics & Analysis

Financial Health

Revenue Growth10.90%
Profit Margin9.69%
P/E Ratio37.6
ROE11.21%
ROA6.54%
Debt/Equity41.95
P/B Ratio3.9
Op. Cash Flow$171.3M
Free Cash Flow$99.0M
Industry P/E30.9

Technical Analysis

TrendNeutral
RSI58.3
Support$280.10
Resistance$328.59
MA 20$302.03
MA 50$321.34
MA 200$310.19
MACDBullish
VolumeStable
Fear & Greed Index87.09

Valuation

Fair Value$154.90
Target Price$341.00
Upside/Downside4.91%
GradeOvervalued
TypeGrowth
Dividend Yield0.42%

Risk Assessment

Beta1.65
Volatility45.72%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.